MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-09-2026
Becton, Dickinson and Company Financial Ratios 2011-2026 | BDX
Annual Financial Ratios Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
33.5 | 37.6 | 45.6 | 37.7 | 34.2 | 79.8 | 56.0 | 191.6 | 41.5 | 36.6 | 41.5 | 20.8 | 15.9 | 13.2 | 13.9 |
P/S |
2.6 | 3.2 | 3.5 | 3.6 | 3.7 | 4.3 | 4.0 | 3.7 | 3.8 | 2.9 | 2.8 | 2.9 | 2.6 | 2.0 | 2.2 |
EPS |
5.8 | 5.9 | 5.0 | 5.9 | 6.9 | 2.8 | 4.0 | 0.6 | 4.7 | 4.6 | 3.4 | 6.1 | 6.6 | 5.7 | 5.8 |
EV (Enterprise Value) |
55.5 B | 62.4 B | 66.1 B | 66 B | 69.1 B | 66.8 B | 99.2 B | 91.3 B | 56.3 B | 52.1 B | 47.1 B | 30.2 B | 25.8 B | 21 B | 22 B |
EBITDA per Share |
17.5 | 16.2 | 15.4 | 15.8 | 15.5 | 10.8 | 16.6 | 16.3 | 13.3 | 15.4 | 11.8 | 11.2 | 9.23 | 10.1 | 10.3 |
EV/EBITDA |
13.6 | 20.1 | 19.6 | 18.9 | 17.2 | 14.0 | 16.8 | 12.3 | 12.6 | 8.7 | 8.4 | ||||
PEG |
3.01 | 15.15 | 24.9 | 5.48 | 8.99 | 61.08 | 0.1 | -2.21 | 17.33 | 1.08 | -0.94 | -2.76 | 0.97 | -13.63 | 5.99 |
P/B |
1.0 | 1.1 | 1.3 | 1.3 | 1.3 | 1.3 | 3.3 | 2.8 | 3.5 | 4.7 | 4.0 | 4.9 | 4.1 | 3.7 | 3.6 |
P/CF |
- | - | - | - | - | - | 29.1 | 30.2 | 25.1 | 19.4 | 26.3 | 22.6 | 22.4 | 12.8 | 15.9 |
ROE % |
6.61 | 6.59 | 5.75 | 7.04 | 8.84 | 3.68 | 5.85 | 1.48 | 8.50 | 12.78 | 9.70 | 23.45 | 25.64 | 28.29 | 26.32 |
ROA % |
3.03 | 2.98 | 2.81 | 3.36 | 3.88 | 1.62 | 2.38 | 0.58 | 2.92 | 3.81 | 2.59 | 9.52 | 10.64 | 10.30 | 12.19 |
ROCE % |
10.16 | 9.26 | 8.18 | 9.03 | 9.50 | 3.84 | 4.85 | 4.80 | 5.33 | 10.19 | 6.69 | 15.73 | 12.53 | 16.60 | 20.49 |
Current Ratio |
- | - | - | - | - | - | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | 2.8 | 2.7 | 2.6 |
DSO |
50.4 | 50.4 | 44.5 | 43.9 | 45.3 | 53.9 | 49.5 | 53.0 | 52.6 | 47.3 | 57.4 | 51.3 | 56.2 | 59.2 | 57.3 |
DIO |
118.5 | 117.5 | 105.8 | 104.8 | 95.4 | 104.7 | 104.6 | 102.6 | 107.9 | 96.6 | 128.0 | 131.6 | 131.8 | 120.6 | 121.6 |
DPO |
59.3 | 58.4 | 54.4 | 60.4 | 53.8 | 48.1 | 44.3 | 46.3 | 47.3 | 37.4 | 41.2 | 35.3 | 31.3 | 34.1 | 29.8 |
Operating Cycle |
168.9 | 167.8 | 150.4 | 148.7 | 140.7 | 158.6 | 154.1 | 155.5 | 160.5 | 144.0 | 185.4 | 182.9 | 188.0 | 179.8 | 178.9 |
Cash Conversion Cycle |
109.6 | 109.4 | 96.0 | 88.3 | 86.9 | 110.4 | 109.8 | 109.3 | 113.2 | 106.6 | 144.2 | 147.6 | 156.7 | 145.7 | 149.1 |
All numbers in USD currency
Quarterly Financial Ratios Becton, Dickinson and Company
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.34 | 2 | 1.07 | 1.05 | 1.68 | 1.85 | 0.97 | 1.37 | 1.54 | 1.71 | - | 1.18 | 1.51 | 2.3 | - | 1.73 | 0.95 | 3.38 | 0.36 | 0.98 | 3.38 | 0.88 | 0.46 | 1.53 | 0.88 | 2.09 | -0.64 | 2.08 | 2.09 | -0.76 | 1.27 | -0.75 | -0.76 | 2.64 | 0.09 | 1.83 | 2.64 | 1.08 | 0.86 | 0.3 | 1.08 | 1.22 | 1.56 | 1.69 | 1.22 | 1.4 | 6.16 | 1.55 | 1.4 | 3.18 | 4.24 | 1.62 | 3.18 | 1.23 | 4.36 | 1.57 | 1.23 |
EBITDA per Share |
4.08 | 4.45 | 3.28 | 3.66 | 3.33 | 3.8 | 3.45 | 3.2 | 3.5 | 4.06 | - | 3.13 | 3.21 | 4.35 | - | 6.01 | 2.69 | 6.18 | 10.3 | 5.05 | 6.18 | 3.8 | 12.4 | 6.48 | 3.8 | 5.39 | 9.2 | 5.06 | 5.39 | 2.29 | 8.51 | 1.36 | 2.26 | 5.04 | 10.2 | 5.09 | 5.04 | 3.03 | 6.79 | 1.97 | 3.03 | 2.53 | 8.35 | 3.71 | 2.53 | 2.68 | 8.1 | 3.44 | 2.68 | 2.65 | 7.48 | 3.51 | 2.65 | 2.19 | 3.99 | 0.92 | 2.31 |
ROE % |
6.19 | 6.56 | 6.40 | 6.29 | 6.65 | 6.56 | 6.47 | 5.36 | 5.64 | 5.70 | 6.50 | 6.83 | 9.00 | 8.42 | 7.50 | 8.04 | 7.07 | 10.03 | 7.27 | 7.51 | 8.44 | 5.54 | 7.03 | 5.61 | 6.30 | 7.84 | 4.40 | 7.57 | 3.72 | -0.18 | 7.87 | 5.59 | 11.72 | 20.13 | 15.89 | 18.17 | 13.93 | 9.76 | 11.25 | 14.68 | 20.26 | 21.74 | 22.42 | 40.31 | 39.85 | 40.65 | 49.30 | 46.74 | 48.66 | 58.31 | 49.89 | 48.70 | 47.90 | 38.23 | 20.11 | 7.11 | 5.45 |
ROA % |
2.86 | 3.04 | 2.99 | 2.96 | 3.17 | 3.14 | 3.11 | 2.57 | 2.63 | 2.62 | 2.93 | 3.06 | 4.03 | 3.76 | 3.35 | 3.59 | 3.15 | 4.46 | 3.16 | 3.24 | 3.58 | 2.26 | 2.85 | 2.29 | 2.52 | 3.09 | 1.72 | 2.83 | 1.38 | -0.09 | 2.47 | 1.68 | 3.55 | 6.11 | 4.67 | 5.28 | 3.99 | 2.66 | 3.06 | 4.81 | 7.19 | 8.22 | 9.20 | 16.67 | 16.54 | 16.91 | 20.03 | 17.89 | 18.28 | 21.51 | 18.44 | 20.00 | 20.41 | 17.42 | 9.31 | 3.29 | 2.52 |
ROCE % |
9.61 | 9.75 | 9.15 | 8.72 | 9.04 | 9.16 | 8.59 | 6.86 | 7.04 | 6.90 | 7.46 | 7.77 | 10.37 | 9.90 | 9.47 | 14.64 | 13.54 | 16.93 | 14.26 | 16.91 | 18.38 | 15.53 | 17.32 | 13.94 | 13.41 | 15.26 | 12.22 | 15.77 | 11.61 | 9.15 | 18.74 | 28.23 | 36.71 | 45.56 | 39.74 | 33.13 | 28.28 | 22.57 | 24.59 | 37.54 | 44.43 | 46.43 | 46.98 | 46.52 | 45.74 | 46.33 | 47.66 | 52.56 | 55.39 | 57.37 | 55.73 | 53.41 | 51.81 | 49.76 | 25.95 | 9.26 | 7.43 |
DSO |
47.4 | 49.5 | 49.0 | 46.2 | 47.1 | 43.6 | 45.4 | 45.1 | 44.4 | 44.5 | - | 22.6 | 43.0 | 45.2 | - | 42.7 | 45.2 | 40.9 | 45.7 | 56.8 | 38.4 | 47.7 | 46.7 | 49.2 | 49.2 | 49.7 | 48.1 | 49.5 | 46.7 | 55.5 | 50.3 | 52.4 | 50.1 | 49.0 | 45.7 | 45.5 | 48.2 | 47.8 | 48.7 | 47.7 | 40.5 | 49.3 | 49.2 | 50.2 | 51.2 | 53.3 | 19.0 | 55.1 | 54.5 | 58.0 | 19.9 | 57.6 | 57.4 | 59.0 | 20.0 | 57.4 | - |
DIO |
129.0 | 121.8 | 114.8 | 110.7 | 110.3 | 108.7 | 117.4 | 119.0 | 128.1 | 127.0 | - | 57.8 | 108.9 | 107.8 | - | 97.2 | 97.4 | 98.2 | 36.0 | 114.0 | 97.2 | 108.4 | 35.2 | 103.4 | 103.6 | 103.8 | 34.9 | 98.9 | 113.0 | 143.0 | 36.5 | 108.3 | 104.7 | 105.9 | 32.6 | 95.0 | 115.0 | 114.0 | 45.2 | 91.9 | 100.4 | 136.4 | 44.8 | 130.4 | 134.3 | 133.6 | 44.6 | 128.8 | 128.6 | 132.7 | 40.6 | 119.5 | 127.7 | 127.0 | 42.8 | 123.1 | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | 32.8 | - | - | - | 23.9 | 8.9 | - | - | 22.2 | 7.5 | - | - | 23.1 | 7.9 | - | - | 23.8 | 8.0 | - | - | 20.6 | 6.3 | - | - | 18.2 | 7.3 | - | - | 18.2 | 6.0 | - | - | 15.5 | 5.3 | - | - | 17.9 | 5.7 | - | - | 15.4 | 5.2 | - | - |
Operating Cycle |
176.4 | 171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 153.0 | - | 139.9 | 142.6 | 139.1 | 81.7 | 170.8 | 135.6 | 156.1 | 81.9 | 152.6 | 152.8 | 153.5 | 83.0 | 148.3 | 159.7 | 198.4 | 86.8 | 160.7 | 154.8 | 154.8 | 78.3 | 140.6 | 163.2 | 161.9 | 93.8 | 139.6 | 140.8 | 185.7 | 94.0 | 180.6 | 185.5 | 186.8 | 63.6 | 183.9 | 183.1 | 190.8 | 60.5 | 177.1 | 185.1 | 186.0 | 62.8 | 180.6 | - |
Cash Conversion Cycle |
176.4 | 171.2 | 163.8 | 156.9 | 157.4 | 152.4 | 162.8 | 164.1 | 172.5 | 171.5 | - | 80.4 | 151.9 | 120.2 | - | 139.9 | 142.6 | 115.2 | 72.8 | 170.8 | 135.6 | 134.0 | 74.4 | 152.6 | 152.8 | 130.4 | 75.1 | 148.3 | 159.7 | 174.6 | 78.8 | 160.7 | 154.8 | 134.2 | 72.0 | 140.6 | 163.2 | 143.6 | 86.6 | 139.6 | 140.8 | 167.5 | 88.0 | 180.6 | 185.5 | 171.3 | 58.3 | 183.9 | 183.1 | 172.9 | 54.7 | 177.1 | 185.1 | 170.5 | 57.6 | 180.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Becton, Dickinson and Company, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Harvard Bioscience
HBIO
|
$ 5.1 | -4.49 % | $ 226 M |  USA |
 |
Repro Med Systems
KRMD
|
$ 4.33 | -2.37 % | $ 200 M | USA |
 |
ICU Medical
ICUI
|
$ 129.02 | -0.7 % | $ 3.18 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.02 | 0.74 % | $ 4.37 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 109.69 | 1.7 % | $ 2.48 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.61 | 0.09 % | $ 25.7 M | USA |
 |
Masimo Corporation
MASI
|
$ 178.5 | 0.03 % | $ 9.51 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 67.86 | -0.39 % | $ 4.01 B | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Nephros
NEPH
|
$ 3.02 | -2.89 % | $ 31.4 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 57.23 | -2.12 % | $ 2.88 B | USA |
 |
Baxter International
BAX
|
$ 16.64 | 0.15 % | $ 8.54 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.13 | 1.46 % | $ 230 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.45 | -2.43 % | $ 427 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 469.14 | -1.86 % | $ 167 B | USA |
 |
AtriCure
ATRC
|
$ 29.48 | -1.01 % | $ 1.41 B | USA |
 |
Pro-Dex
PDEX
|
$ 49.65 | 3.55 % | $ 163 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.6 | 0.05 % | $ 198 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.22 | 1.36 % | $ 1.43 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 118.02 | -0.1 % | $ 3.78 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.61 | 2.3 % | $ 903 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.29 | 2.44 % | $ 23.1 M | USA |
 |
Repligen Corporation
RGEN
|
$ 116.33 | -0.02 % | $ 6.48 M | USA |
 |
electroCore
ECOR
|
$ 6.17 | 0.65 % | $ 52.3 K | USA |
 |
The Cooper Companies
COO
|
$ 70.22 | -0.03 % | $ 14 B | USA |
 |
STERIS plc
STE
|
$ 223.63 | 1.17 % | $ 22 B | USA |
 |
Stereotaxis
STXS
|
$ 1.76 | -4.35 % | $ 160 M | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 106.54 | 0.54 % | $ 4.75 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 105.6 | -1.15 % | $ 5.11 B | USA |
 |
ResMed
RMD
|
$ 229.38 | 0.59 % | $ 33.5 B | USA |
 |
Utah Medical Products
UTMD
|
$ 64.34 | -1.21 % | $ 233 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.47 | -1.93 % | $ 25.2 M |  Israel |
 |
Retractable Technologies
RVP
|
$ 0.73 | 0.69 % | $ 21.9 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 245.83 | 1.75 % | $ 17.8 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 19.02 | 2.76 % | $ 943 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.63 | 0.74 % | $ 2.32 B | USA |
 |
Alcon
ALC
|
$ 74.14 | 0.03 % | $ 40.4 B |  Schweiz |